- Home
- PHAT vs BCX Comparison
PHAT vs BCX Comparison
Compare PHAT & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- BCX
- Stock Information
- Founded
- PHAT 2018
- BCX 2011
- Country
- PHAT United States
- BCX United States
- Employees
- PHAT N/A
- BCX N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- BCX Finance/Investors Services
- Sector
- PHAT Health Care
- BCX Finance
- Exchange
- PHAT Nasdaq
- BCX Nasdaq
- Market Cap
- PHAT 727.5M
- BCX 725.6M
- IPO Year
- PHAT 2019
- BCX N/A
- Fundamental
- Price
- PHAT $9.80
- BCX $9.40
- Analyst Decision
- PHAT Strong Buy
- BCX
- Analyst Count
- PHAT 5
- BCX 0
- Target Price
- PHAT $16.40
- BCX N/A
- AVG Volume (30 Days)
- PHAT 4.9M
- BCX 370.6K
- Earning Date
- PHAT 08-07-2025
- BCX 01-01-0001
- Dividend Yield
- PHAT N/A
- BCX 6.99%
- EPS Growth
- PHAT N/A
- BCX N/A
- EPS
- PHAT N/A
- BCX N/A
- Revenue
- PHAT $81,859,000.00
- BCX N/A
- Revenue This Year
- PHAT $195.45
- BCX N/A
- Revenue Next Year
- PHAT $106.76
- BCX N/A
- P/E Ratio
- PHAT N/A
- BCX N/A
- Revenue Growth
- PHAT 3055.70
- BCX N/A
- 52 Week Low
- PHAT $2.21
- BCX $8.25
- 52 Week High
- PHAT $19.71
- BCX $9.90
- Technical
- Relative Strength Index (RSI)
- PHAT 66.25
- BCX 53.19
- Support Level
- PHAT $8.86
- BCX $9.22
- Resistance Level
- PHAT $11.21
- BCX $9.43
- Average True Range (ATR)
- PHAT 1.59
- BCX 0.10
- MACD
- PHAT -0.06
- BCX -0.03
- Stochastic Oscillator
- PHAT 63.60
- BCX 51.52
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About BCX BlackRock Resources of Beneficial Interest
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.